Search results
A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?
Investor's Business Daily· 1 year agoIt's a new day at Bristol Myers Squibb, according to a company executive. But BMY stock remains...
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
Barrons.com· 2 months agoBARRON'S COVER - MAIN Understanding the products from pharmaceutical companies could be the most...
Exelixis (EXEL) Reports Positive EU Patent Ruling for Cabometyx
Zacks via Yahoo Finance· 4 months agoExelixis, Inc. EXEL announced that it has successfully defended an EU patent for Cabometyx...
US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent
Reuters via Yahoo News· 1 year agoWASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals...
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
Investor's Business Daily· 1 year agoMerck is acquiring immunology-focused drugmaker Prometheus Bio in a well-timed $10.8 billion deal...
How an Innovative Deal Will Give Millions Access to Cheaper Tuberculosis Drugs
Time via Yahoo News· 11 months agoWhy a new deal between Johnson & Johnson and the non-profit Global Drug Facility means that the...
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
GuruFocus.com via Yahoo Finance· 4 months agoStrengths: Robust product portfolio and strategic acquisitions bolstering oncology and neuroscience...
Novartis (NVS) to Appeal to Supreme Court for Gilenya Patent
Zacks via Yahoo Finance· 2 years agoNovartis (NVS) is looking to defend its patents for the multiple sclerosis drug Gilenya and file a...
Vertex Is Worth Your Attention
GuruFocus.com via Yahoo Finance· 2 months agoVertex Pharmaceuticals Inc. (NASDAQ:VRTX) recently announced a clinical trial for a potentially life-changing molecule for the most common inherited...
Decoding Pfizer Inc (PFE): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 4 weeks agoStrengths highlight Pfizer's robust product portfolio and global market presence. Weaknesses underscore the challenges in revenue fluctuations and patent...